Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Down 6.57%
As of Tuesday, October 06, Oruka Therapeutics, Inc.’s ORKA share price has dipped by 6.57%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Commentary & Analysis
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Down 5.14%
As of Thursday, September 24, Oruka Therapeutics, Inc.’s ORKA share price has dipped by 5.14%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Down 7.66%
As of Thursday, September 24, Oruka Therapeutics, Inc.’s ORKA share price has dipped by 7.66%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Down 5.52%
As of Wednesday, September 23, Oruka Therapeutics, Inc.’s ORKA share price has dipped by 5.52%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Oruka Therapeutics, Inc.’s (ORKA) Stock Is Down 7.50%
As of Wednesday, September 23, Oruka Therapeutics, Inc.’s ORKA share price has dipped by 7.50%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $5,308.7 | $241.3 | 69% |
|
| Shares Out (Mil) | 62.9 | 53.9 | 53% |
|
| Institutional Ownership | 97.9% | 93.1% | 76% |
|
| Float (Mil) | 56.9 | 41.4 | 50% |
|
| Beta | -0.21 | 0.95 | 3% |
|
| Avg Daily Volume (000s) | 1,086 | 646 | 71% |
|
| Price Change (52-week) |
305.2% | 49.4% | 99% |
|
| Growth | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.618) | ($2.366) | ($2.862) | |
| Month Ago EPS | ($0.618) | ($2.366) | ($2.862) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.507) | ($2.039) | ($2.492) | |
| Year/Year Chg | 11.4% | 28.0% | 105.4% | |
| Financials | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($133) | ($44) | 9% |
|
| EPS (TTM) | ($2.024) | ($1.600) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($101) | ($33) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $203 | $2 | 84% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 20% |
|
| Enterprise Value (Q1) (Mil) | $5,063 | $174 | 63% |
|
| Valuation | ORKA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.41 | 2.33 | 76% |
|
| P/E | na | 18.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ORKA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (17.8%) | (47.7%) | 21% |
|
| ROE | (18.3%) | (54.6%) | 24% |
|
| Liabilities to Assets | 2.2% | 29.3% | 1% |
|
| F-Score | 4 | 2 | 33% |
|
Oruka Therapeutics, Inc. did not pass any screens on 10/6/2026.
